Results 101 to 110 of about 2,475,393 (270)

Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? [PDF]

Pharmacol Res Perspect, 2022
Jones L, Jones AM.
europepmc   +1 more source

Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single-Center, Single-Arm, Phase I Study in China. [PDF]

Clin Pharmacol Drug Dev
Abstract This single‐center, single‐arm, Phase I study evaluated drug–drug interactions (DDIs) between cofrogliptin and metformin in healthy Chinese subjects. Twenty‐two subjects sequentially received metformin monotherapy (Days 1–4), cofrogliptin monotherapy (Days 6–34), and combination therapy (Days 38–47).
Cui C, Liu N, Chu C, Niu S, Huang Y, Li F, Li Y, Li H, Liu D.   +8 more
europepmc   +2 more sources

A Novel Orally Active Sulfonamide Compound Dipeptidyl Peptidase IV Inhibitor: Structure and Activity Relationship of Arylsulfonamide to Dipeptidyl Peptidase IV Inhibition

, 2012
[[abstract]]Diabetes mellitus is a chronic disease characteristic of poor glucose homeostasis that requires constant monitoring and adjustment of blood glucose levels by exogenous intervention.
蔡建鈞;Tsai, Henry J;Chou, Shan-Yen;Chuang, SH;Chen, CC;Hsu, FL
core  

Crystal structures of trypanosoma brucei oligopeptidase B broaden the paradigm of catalytic regulation in prolyl oligopeptidase family enzymes [PDF]

, 2013
Oligopeptidase B cleaves after basic amino acids in peptides up to 30 residues. As a virulence factor in bacteria and trypanosomatid pathogens that is absent in higher eukaryotes, this is a promising drug target.
Rory E Morty, Canning Peter, Rea, Dean, Dean Rea (483664), Morty Rory E., Morty, Rory E., Dean Rea, Vilmos Fülöp, Rory E. Morty (341515), Canning, Peter, Fülöp, Vilmos, Peter Canning, Peter Canning (483663), Vilmos Fülöp (483665), Rea Dean, Fülöp Vilmos   +15 more
core   +2 more sources

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes. [PDF]

Front Endocrinol (Lausanne), 2021
Liu X, Liu Y, Liu H, Li H, Yang J, Hu P, Xiao X, Liu D.   +7 more
europepmc   +1 more source

Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV.

, 2006
Udgivelsesdato: 2006-Jun-1Dipeptidyl peptidases 8 and 9 have been identified as gene members of the S9b family of dipeptidyl peptidases. In the present paper, we report the characterization of recombinant dipeptidyl peptidases 8 and 9 using the ...
Christensen, Jesper, Nielsen, Per F, Branner, Sven, Kanstrup, Anders B., Wagtmann, Nicolai, Kanstrup, Anders B, Bjelke, Jais R, Bjelke, Jais R., Nielsen, Per F., Rasmussen, Hanne B., Rasmussen, Hanne B   +10 more
core   +1 more source

Frailty and low body mass index as key determinants of sodium‐glucose cotransporter 2 inhibitor‐specific adverse event‐related discontinuation in adults aged ≥75 years: A multicenter real‐world retrospective cohort study

Journal of Diabetes Investigation, EarlyView.
Among Japanese adults aged ≥75 years newly initiating SGLT2 inhibitors, SGLT2 inhibitor–specific adverse event‐related discontinuation occurred in 9.1% within 180 days. Frailty and low BMI, rather than chronological age, were the key predictors, highlighting the importance of assessing physiological reserve before treatment initiation.
Taisuke Uchida, Hiroaki Ueno, Ayaka Konagata, Hiroki Nabekura, Yuki Kikuchi, Takumi Beppu, Akari Sekishima, Hirotaka Sekishima, Takayuki Nakamura, Fumiko Kogo, Yudai Uehira, Yuri Tanaka, Hideki Yamaguchi, Kazuya Shimoda   +13 more
wiley   +1 more source

D-420720, A Novel Orally Active Sulfonamide Compound Dipeptidyl Peptidase IV Inhibitor: Structure and Activity Relationship of Arylsuffonamide to Dipeptidyl Peptidase IV Inhibition [PDF]

, 2010
[[abstract]]Diabetes mellitus is a chronic disease characteristic of poor glucose homeostasis that requires constant monitoring and adjustment of blood glucose levels by exogenous intervention.
Tsai, HJ (Tsai, Henry J.); Chou, SY (Chou, Shan-Yen); Chuang, SH (Chuang, Shih-Hsien); Chen, CC (Chen, Chien-Cheng); Hsu, FL (Hsu, Feng-Lin)
core  

SGLT2i use and fracture risk compared with DPP4i in patients with T2DM

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction The association between sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) use and fracture risk remains inconclusive. Most previous studies have focused on treatment‐naïve patients, despite many patients in routine clinical practice initiating SGLT2i therapy after prior dipeptidyl peptidase‐4 inhibitor (DPP4i) use.
Sung‐Yen Lin, Shih‐Hao Huang, Ching‐Han Chiang, Cheng‐Jung Ho, Chung‐Hwan Chen, Li‐Nien Chien   +5 more
wiley   +1 more source